Cancer Genetics to Report Biomarker Findings in Metastatic Clear Cell Renal Carcinoma Using a CGI-Designed NGS Panel at the 14th International Kidney Cancer Symposium in Miami, FL

RUTHERFORD, N.J., Nov. 07, 2015 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), an emerging leader in DNA-based cancer diagnostics, announced the presentation of results from a University of Utah (Huntsman Cancer Institute)-led research study at the 14th International Kidney Cancer Symposium in Miami, Florida, on November 7th, 2015. The study entitled, “Molecular Predictors of Response and Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma (mccRCC) Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors (VEGFTKIs)” was conducted as a collaboration between Dr. Neeraj Agarwal and CGI. The aim of the study was to investigate molecular markers predictive of response to targeted therapy, to allow better patient selection and guide towards more customized and effective therapy.

The HCI and Cancer Genetics teams worked jointly to identify molecular abnormalities or markers in the tumor samples of 89 mccRCC patients treated with targeted therapy. The specimens were subjected to DNA sequencing using a NGS panel designed by CGI specifically for renal cancer and to whole genome array-comparative genomic hybridization. After independent validation, the results of the study will aid in better selection of patients for given treatments, thus minimizing toxicities, managing costs, and facilitating individualized therapy.

Details for the presentation are the following:

Event Name: 14th International Kidney Cancer Symposium in Miami, FL
Date and Time: November 7th, 2015, 2.45PM ET
Study Title: Molecular Predictors of Response and Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma (mccRCC) Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors (VEGFTKIs).

About Cancer Genetics

Cancer Genetics Inc. is an emerging leader in DNA-based cancer diagnostics. Our tests target difficult to diagnose hematological, urogenital and HPV-associated cancers. They are designed to guide the prognosis and treatment of these cancers with the goal of improving outcomes for patients. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.

We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals and biopharmaceutical companies. Our state-of-the-art reference labs are CLIA certified and CAP accredited in the US and have licensure from several states including New York State.

For more information, please visit or follow us:

Internet: http://www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Forms 10-K for the year ended December 31, 2014 and 10-Q for the quarter ended June 30, 2015 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.

Media Contact: Cancer Genetics, Inc. Marie-Agnes Patrone-Michellod, PhD. Tel: 201.528.9200 Email: marie.michellod@cgix.com

Source:Cancer Genetics, Inc.